Miracor Medical Systems GMBH
This article was originally published in Start Up
Executive Summary
Miracor Medical Systems aims to improve post-PCI myocardial infusion to repair the damage caused by heart attacks. The company has developed minimally invasive technology to intermittently occlude the coronary sinus to block venous outflow from the heart. The resulting rise in pressure redistributes blood in the myocardium, where Miracor believes it will regenerate damaged tissue and lead to improved outcomes for patients.
You may also be interested in...
Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions
When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.
Start-Up Previews (10/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.
Start-Up Previews (10/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.